prostate biopsy

From Aaushi
Jump to navigation Jump to search

Indications

Procedure

Radiology

Complications

Comments:

  • it seems that the majority of hospitalizations are not accounted for by the given complication rates (1.0 + 0.3 + 0.3 = 1.6 << 6.9-2.9 = 4)
  • is a prostate biopsy for a man with an otherwise 2.9% 30 day hospitalization rate indicated?

Notes

  • lack of evidence rebiopsy after 1st negative biopsy reduces morbidity & mortality[1]

More general terms

Additional terms

References

  1. 1.0 1.1 Journal Watch 21(24):195, 2001 Djavan B et al Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166:1679, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11586201
  2. 2.0 2.1 Loeb S et al. Complications after prostate biopsy: Data from SEER-Medicare. J Urol 2011 Nov; 186:1830 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21944136
  3. 3.0 3.1 Rosario DJ et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study. BMJ 2012 Jan 9; 344:d7894. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22232535
  4. 4.0 4.1 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
  5. 5.0 5.1 Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/9605898
  6. 6.0 6.1 Siddiqui MM et al Comparison of MR/Ultrasound Fusion-Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer JAMA. 2015;313(4):390-397 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25626035 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=2091987
    Schwartz LH, Basch E MR/Ultrasound Fusion-Guided Biopsy in Prostate Cancer. What Is the Evidentiary Standard? JAMA. 2015;313(4):367-368 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25626034 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=2091964
  7. 7.0 7.1 Mehralivand A, Shih JH, Rais-Bahrami S et al A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncol. Published online February 22, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29470570 https://jamanetwork.com/journals/jamaoncology/article-abstract/2673079
  8. 8.0 8.1 Kasivisvanathan V, Rannikko AS, Borghi M et al MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. March 19, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29552975 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1801993
  9. 9.0 9.1 9.2 9.3 Wolinsky H, MedPage Today. August 19, 2018 https://www.medpagetoday.com/special-reports/apatientsjourney/74624
  10. 10.0 10.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  11. 11.0 11.1 Wei JT et al. Early detection of prostate cancer: AUA/SUO guideline part II: Considerations for a prostate biopsy. J Urol 2023 Jul; 210:54. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37096575 https://www.auajournals.org/doi/10.1097/JU.0000000000003492
  12. 12.0 12.1 Hu JC, Assel M, Allaf ME et al. Transperineal vs transrectal prostate biopsy - The PREVENT randomized clinical trial. JAMA Oncol. 2024 Sep 19:e244000 [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/39298143 https://jamanetwork.com/journals/jamaoncology/fullarticle/2823969